泓博医药(301230) - 2025 Q2 - 季度业绩预告

Shanghai Hongbo Zhuyuan Pharmaceutical Co., Ltd. 2025 Semi-Annual Performance Forecast Current Period Performance Forecast The company forecasts significant profit growth for H1 2025, with net profit attributable to shareholders expected to increase by 43.96% to 69.00% and non-recurring net profit by 91.99% to 134.66% Performance Forecast for the Current Period | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: RMB 23 million - RMB 27 million | Profit: RMB 15.9765 million | | | Year-on-Year Growth: 43.96% - 69.00% | | | Net Profit Excluding Non-Recurring Gains/Losses | Profit: RMB 18 million - RMB 22 million | Profit: RMB 9.3753 million | | | Year-on-Year Growth: 91.99% - 134.66% | | Communication with Accounting Firm The company explicitly states that the financial data in this performance forecast has not been audited by an accounting firm - The financial data in this performance forecast has not been audited by an accounting firm[4] Explanation of Performance Changes The company's H1 2025 performance growth is primarily driven by robust core business operations and positive non-recurring gains Operating Performance Growth The company's core business segments, including drug discovery and commercial production, achieved strong year-on-year and sequential revenue growth, with overall revenue projected to increase by over 30% - In H1 2025, all company business segments, including drug discovery, process research and development, and commercial production, achieved both year-on-year and sequential revenue growth[5] - Overall company operating revenue is projected to increase by over 30% year-on-year in H1 2025[5] - During the reporting period, an increase in active customers accelerated new order growth and enhanced the company's one-stop integrated service capabilities[6] Impact of Non-Recurring Gains/Losses Non-recurring gains and losses contributed approximately RMB 4.6 million to net profit, mainly from fair value changes in wealth management products and government subsidies - During the reporting period, non-recurring gains and losses contributed approximately RMB 4.6 million to the company's net profit, mainly from fair value changes in unexpired wealth management products and government subsidies[6] Other Relevant Information The company advises investors that this performance forecast is a preliminary estimate, with final financial data subject to the official 2025 semi-annual report, urging caution regarding investment risks - This performance forecast is a preliminary estimate by the company's finance department, with specific financial data subject to the company's officially disclosed 2025 semi-annual report[7]